Insider trading activity has recently indicated mixed sentiment for two prominent stocks: Waste Management and Ionis Pharmaceuticals. In early 2026, Waste Management saw its stock reach an all-time high, prompting insiders to collectively sell about $25 million in shares. However, institutional accumulation remains robust, and the company’s dividend growth prospects are contributing to a bullish long-term outlook. Analysts highlight that despite insider selling, institutional ownership is strong, with 80% of shares held by institutions, and there is a positive reception to future earnings potential.
Conversely, Ionis Pharmaceuticals is experiencing a more cautious environment, characterized by increased insider and institutional selling. While analysts project a 25% upside for Ionis fueled by the anticipated success of its drug Olezarsen, the heavy selling by insiders and institutions poses challenges. Notably, institutions own over 90% of Ionis, and they have been taking profits after substantial gains over the past year, which complicates the stock’s immediate outlook.
Both companies have seen pullbacks from their recent highs, potentially creating investment opportunities for those willing to overlook short-term volatility. Analysts maintain a moderate bullish stance on both stocks, with the prospect of further growth driven by favorable long-term fundamentals.
- Why this story matters: Insights into insider trading can inform investor sentiment and potential stock performance.
- Key takeaway: Waste Management remains strong due to dividends and institutional support, while Ionis Pharmaceuticals faces headwinds amid insider selling despite growth projections.
- Opposing viewpoint: Some analysts express caution regarding the immediate prospects for both companies due to the significant insider selling activity.
